Effects of menstrual cycle periodic Chinese medicine prescription on endometriosis infertility patients

doi:10.12092/j.issn.1009-2501.2018.06.012

Abstract

Abstract:

AIM: To investigate the application of menstrual cycle periodic Chinese medicine prescription in endometriosis (EMs) infertility patients, and to provide a reference for the clinical treatment of EMs infertility patients. METHODS: A total of 74 infertility patients with EMs from March 2014 to July 2016 who met the inclusion criteria in our hospital were selected, and were randomly divided into observation group (n=37) and control group (n=37) according to the random number table method. The control group was treated with dydrogesterone tablets, while the observation group was treated with menstrual cycle periodic Chinese medicine prescription based on the control group. The clinical effect, immune function, ovarian function and pregnancy outcome were compared between the two groups. RESULTS: The total effective rate of clinical treatment in observation group was significantly higher than that of control group (P<0.05). Before treatment, there were no significantly differences in the level of CD3⁺, CD4⁺, CD4⁺ /CD8⁺, natural kille (NK), estradiol 2 (E2) and anti-mullerian hormone (AMH) between the two groups (P>0.05). After treatment, the level of CD3⁺, CD4⁺, CD4⁺ /CD8⁺ , NK E2 and AMH were significantly better than those of before treatment (P<0.05), and the observation group was significantly better than the control group (P<0.05). Before treatment, there were no significantly differences in the level of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) between the two groups (P>0.05). After treatment, the level of LH and FSH were significantly lower than those of before treatment (P<0.05), and the observation group was significantly lower than the control group (P<0.05). The success rate of pregnancy in observation group was significantly higher than that of control group (P<0.05). CONCLUSION: The menstrual cycle periodic Chinese medicine prescription can adjust the immune function, improve the ovarian function, and increase the pregnancy rate of the EMs infertile patients.

Key words: menstrual cycle, periodic, Chinese medicine prescription, endometriosis infertility

CLC Number:

R711.71

GAO Tao, FANG Xiaohong, MA Jing, CHU Yun, CHEN Bixia. Effects of menstrual cycle periodic Chinese medicine prescription on endometriosis infertility patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 672-677.

References

［1］于月新,李亚里.子宫内膜异位症中转化生长因子-β作用机制及临床意义的研究进展［J］.解放军医学院学报,2016,37(11):1197-1199.
［2］刘瑞景，蔡海燕.子宫内膜异位症发病机制及其治疗分类研究［J］.中国医学创新，2017，14（6）：145-148.
［3］杨如萌,张轶清.子宫内膜异位症的研究进展［J］.湖北科技学报(医学版),2016, 30(1):89-91.
［4］吴秀芳,陈琛,王迎.子宫内膜异位症生育指数对内异症合并不孕患者术后妊娠的指导价值［J］.现代仪器与医疗,2017,23(5):96-97.
［5］孙彦,车艳辞.腹腔镜手术联合药物治疗子宫内膜异位症临床效果的Meta分析［J］.现代妇产科进展,2015,24(1):37-39.
［6］张少萍.子宫内膜异位症的中医中药治疗［J］.内蒙古中医药,2015,34(1):43-44.
［7］中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症诊断与治疗规范［J］. 中华妇产科杂志,2007,42(9):645-648.
［8］李萌,夏天,王宝娟.不同治疗方案对子宫内膜异位症合并不孕患者生育影响的研究进展［J］.生殖与避孕,2015,35(7):478-483.
［9］蔡婷,姜锐.腹腔镜术后辅以散结镇痛汤治疗子宫内膜异位症合并不孕临床研究［J］.中医药信息,2017,34(1):104-106.
［10］马遇春,孙博,丛慧芳.子宫内膜异位症中医内治法研究进展［J］.医学综述,2015,21(11):2036-2038.
［11］李杏杏,万贵平.中药治疗子宫内膜异位症作用机制的研究进展［J］.现代中西医结合杂志,2015,24(2):210-213.
［12］赵瑞华,唐仪.子宫内膜异位症相关不孕症中医治疗经验［J］.北京中医药,2015,34(4):288-290.
［13］陈建梅,刘姣,秦翠梅,等.莪术水煎液、配方颗粒及莪术油抗痛经作用的比较研究［J］.中药药理与临床,2016,32(4):60-63.
［14］赵永见,牛凯,唐德志,等.桃仁药理作用研究近况［J］.辽宁中医杂志,2015,42 (4):888-890.
［15］侯新新,王晓秋,李大金.不同T细胞亚群及与其他免疫细胞协同作用参与子宫内膜异位病灶的形成和发展［J］.现代免疫学,2016,36(4):333-336.
［16］李岩.白芍及其化学成分的药理研究进展［J］.职业与健康,2015,31(15):2153-2156.
［17］孙秀玲,姜明霞.黄芪药理作用机制的研究进展［J］.中医临床研究,2015,7(17): 140-141.
［18］孙森凤,张颖颖,褚万春.黄柏药理作用的研究进展［J］.山东化工,2017,46(14): 99-100.
［19］张晓芳,张宜群.滋阴补阳中药对子宫内膜异位症合并不孕患者血清性激素水平与妊娠结局的影响研究［J］.中国性科学,2016,25(4):129-132.
［20］赵文静,王历,王芝兰,等.淫羊藿的药理作用及临床应用研究进展［J］.中医药信息,2016,33(2):105-108.
［21］何恩惠.续断的药理分析与中药配伍［J］.世界最新医学信息文摘,2015,15(66): 251.

[1]	SHEN Longde, LI Ailu, LI Lichun, WU Yinyin, SHEN Longyuan, JIANG Qiuxia, HE Jinxi, WU Zhifen, YU Liji, ZHANG Xiaohong. Experimental study on the effect of curcumin on endometriosis in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 862-868.
[2]	SHI Yin, RUAN Fan, ZHENG Ying. Safety and efficacy of Guizhi Fuling capsule in improving postoperative pregnancy outcome in patients with mild endometriosis infertility [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1392-1396.
[3]	XU Zhihui, ZHOU Jiechun, CHEN Huinan, WANG Anlan. Application and effect of intrauterine injection of human chorionic gonadotropin in frozen-thawed embryo transfer cycle for endometriosis patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1287-1291.
[4]	GUI Hua, CAO Shanshan, ZHAO Qiaoyun, WANG Peihong. Effects of climen associated with goserelin on serum hormone levels of laparoscopic surgery in patients with endometriosis after laparoscopic hysterectomy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 557-560.
[5]	LV Hongqing, SHAO Mingjun, HU Meixu, HU Min. Effects of mifepristone on sex hormones and cytokines in patients undergoing laparoscopic endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 180-183.
[6]	SHI Shao-quan, HONG Ting, JIANG Fang-fang, WANG Gui-rong, WANG Feng. Letrozole combined with gestrinone compared with gestrinone alone in the treatment of endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1275-1279.
[7]	ZHANG Hui-zhen. Therapeutic effect of treatment with surgery and mifepristone in patients with endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(5): 593-595.
[8]	XU Lan, ZHANG Yong-fen, ZHANG Xiao-hong. Clinical evaluation of mifepristone added after laparoscopy in treatment of patients with endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(7): 824-827.